COMPANY PROFILE // THE 014 REPORT
Viking Therapeutics, Inc.
VKTX (Nasdaq)
Assembled from 3 government sources in 0.2 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber8-K Item 4.01 filed: change in the company's certifying accountant (auditor) on 2025-04-23 (last 24 months).
- InfoGLEIF: no direct parent reported; reporting exception reason NATURAL_PERSONS.
✓ SEC filings✓ LEI✓ State registrationpossible match✗ SAM registration✗ IRS return✗ Website✗ Lobbying registration
No SAM registration, no IRS return, no website, no lobbying registration on record.
Viking Therapeutics, Inc. is an SEC-registered operating company in pharmaceutical preparations, incorporated in DE, based in San Diego, CA; listed as VKTX (Nasdaq).[source] It reported revenue of $0 for the fiscal year ended 2025-12-31.[source] It has filed 49 documents with the SEC in the last 12 months; the latest is a SCHEDULE 13G/A, filed 2026-11-05.[source] Its largest institutional holders on 13F filings are FMR LLC, BlackRock, Inc., STATE STREET CORP (as of 2026-06-30).[source] Seraphix flags 1 item from these records: 8-K Item 4.01 filed.[source]
- red0
- amber1
- info1
- FMR LLC$247.2M
- BlackRock, Inc.$241.5M
- STATE STREET CORP$218.7M
- VANGUARD CAPITAL MANAGEMENT LLC$197.1M
- VANGUARD PORTFOLIO MANAGEMENT LLC$174.9M
- TWO SIGMA INVESTMENTS, LP$153.6M
- AMERIPRISE FINANCIAL INC$84.1M
- GEODE CAPITAL MANAGEMENT, LLC$81.9M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Aubuchon Neil William · Chief Commercial Officer (Officer) · latest Form 4 2026-03-10 · filing · LinkedIn search
- Lian Brian · President & CEO (Director,Officer) · latest Form 4 2026-01-05 · filing · LinkedIn search
- Mancini Marianna · Chief Operating Officer (Officer) · latest Form 4 2026-01-05 · filing · LinkedIn search
- ZANTE GREG · Chief Financial Officer (Officer) · latest Form 4 2026-01-05 · filing · LinkedIn search
- FOEHR MATTHEW W · Director · latest Form 4 2026-01-05 · filing · LinkedIn search
- MACARTNEY LAWSON · Director · latest Form 4 2026-01-05 · filing · LinkedIn search
- Rouan Sarah Kathryn · Director · latest Form 4 2026-01-05 · filing · LinkedIn search
- Rowland Charles A Jr · Director · latest Form 4 2026-01-05 · filing · LinkedIn search
- SINGLETON J MATTHEW · Director · latest Form 4 2026-01-05 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Legal counsel, as publicly named
- Paul Hastings LLP · Exhibit 5.1 legal opinion, S-3ASR filed 2026-07-30
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001607678 | source |
| LEI | 529900IVC72YPFA25M37 | source |
| EIN | 46-1073877 | source |
| NY DOS ID | 4302196 | record |
| Business address (SEC) | 9920 PACIFIC HEIGHTS BLVD, SUITE 500, SAN DIEGO, CA | source |
Does not exist in the records we hold: UEI, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-01 · in 101 days · Next 10-K due (period ended 2026-12-31; Large accelerated filer) (computed from the fiscal year end and filer status)
- 2027-05-10 · in 171 days · Next 10-Q due (period ended 2027-03-31; Large accelerated filer) (computed from the fiscal year end and filer status)
- 2027-10-01 · in 315 days · LEI next renewal (529900IVC72YPFA25M37)
PEERS BY SIC CODE
Industry context
SIC 2834 (pharmaceutical preparations): 568 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- PFIZER INC · 124 SEC filings in 12 months · $25.74B federal (possible match)
- Merck & Co., Inc. · 150 SEC filings in 12 months · $13.51B federal (possible match)
- ABBOTT LABORATORIES · 118 SEC filings in 12 months · 1 flag · $2.64B federal (possible match)
- ASTRAZENECA PLC · 140 SEC filings in 12 months · $602.8M federal (possible match)
- TEVA PHARMACEUTICAL INDUSTRIES LTD · 168 SEC filings in 12 months · $77.6M federal (possible match)
- NOVARTIS AG · 34 SEC filings in 12 months · $41.9M federal (possible match)
- Spero Therapeutics, Inc. · 41 SEC filings in 12 months · 4 flags · $39.5M federal (possible match)
- Grifols SA · 18 SEC filings in 12 months · $22.5M federal (possible match)
- SCYNEXIS INC · 54 SEC filings in 12 months · 3 flags · $18.5M federal (possible match)
- Ensysce Biosciences, Inc. · 45 SEC filings in 12 months · 3 flags · $15.1M federal (possible match)
- UNITED THERAPEUTICS Corp · 454 SEC filings in 12 months · 2 flags · $6.8M federal (possible match)
- Zoetis Inc. · 144 SEC filings in 12 months · 1 flag · $6.7M federal (possible match)
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- OmniAb, Inc. · FOEHR MATTHEW W
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-10-29 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-10-28 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-09-28 filing 8-K items 1.01,2.03,9.01 · SEC EDGAR
- 2026-09-25 filing 424B5 · SEC EDGAR
- 2026-09-25 filing 424B5 · SEC EDGAR
- 2026-09-24 filing FWP · SEC EDGAR
- 2026-09-24 filing 305B2 · SEC EDGAR
- 2026-09-23 filing 424B5 · SEC EDGAR
- 2026-09-23 filing 424B5 · SEC EDGAR
- 2026-09-22 filing 8-K items 8.01,9.01 · SEC EDGAR
- 2026-07-30 filing S-3ASR · SEC EDGAR
- 2026-07-29 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-07-29 filing 144 · SEC EDGAR
- 2026-07-29 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-07-29 filing 144 · SEC EDGAR
- 2026-07-29 filing 144 · SEC EDGAR
- 2026-05-26 filing 8-K items 5.07,9.01 · SEC EDGAR
- 2026-04-30 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-04-29 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-04-01 filing ARS · SEC EDGAR
- 2026-04-01 filing DEFA14A · SEC EDGAR
- 2026-04-01 filing Proxy statement · SEC EDGAR
- 2026-02-11 filing Annual report (10-K) · SEC EDGAR
- 2026-02-11 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-01-26 insider First Form 3/4/5 on record for Aubuchon Neil William (Chief Commercial Officer) · SEC Forms 3/4/5
- 2026-01-05 filing 144 · SEC EDGAR
- 2026-01-05 filing 144 · SEC EDGAR
- 2026-01-05 filing 144 · SEC EDGAR
- 2026-01-05 insider First Form 3/4/5 on record for MACARTNEY LAWSON (Director) · SEC Forms 3/4/5
- 2026-01-05 insider First Form 3/4/5 on record for SINGLETON J MATTHEW (Director) · SEC Forms 3/4/5
170 earlier entries
- 2026-01-02 filing 144
- 2025-10-28 filing 144
- 2025-10-28 filing 144
- 2025-10-28 filing 144
- 2025-10-28 insider First Form 3/4/5 on record for Rowland Charles A Jr (Director)
- 2025-10-27 filing 144
- 2025-10-23 filing Quarterly report (10-Q)
- 2025-10-22 filing 8-K items 2.02,9.01
- 2025-08-19 filing 8-K items 7.01,9.01
- 2025-07-23 filing Quarterly report (10-Q)
- 2025-07-23 filing 8-K items 2.02,9.01
- 2025-07-03 filing 144
- 2025-07-03 filing 144
- 2025-07-03 filing 144
- 2025-07-03 insider First Form 3/4/5 on record for Lian Brian (President & CEO)
- 2025-07-03 insider First Form 3/4/5 on record for Mancini Marianna (Chief Operating Officer)
- 2025-07-03 insider First Form 3/4/5 on record for ZANTE GREG (Chief Financial Officer)
- 2025-05-27 filing 8-K items 5.07,9.01
- 2025-04-24 filing Quarterly report (10-Q)
- 2025-04-23 filing DEFA14A
- 2025-04-23 filing DEFR14A
- 2025-04-23 filing 8-K items 2.02,9.01
- 2025-04-23 filing 8-K items 4.01,8.01,9.01
- 2025-04-21 filing UPLOAD
- 2025-04-14 insider First Form 3/4/5 on record for FOEHR MATTHEW W (Director)
- 2025-04-08 filing CORRESP
- 2025-04-08 filing ARS
- 2025-04-08 filing DEFA14A
- 2025-04-08 filing Proxy statement
- 2025-04-02 insider First Form 3/4/5 on record for Rouan Sarah Kathryn (Director)
- 2025-03-31 filing UPLOAD
- 2025-03-11 filing 8-K items 1.01,2.03,8.01,9.01
- 2025-02-26 filing Annual report (10-K)
- 2025-02-05 filing 8-K items 2.02,9.01
- 2025-01-06 filing 144
- 2025-01-06 filing 144
- 2025-01-06 filing 144
- 2024-11-08 filing 144
- 2024-11-04 filing 8-K items 7.01,9.01
- 2024-10-28 filing 144
- 2024-10-25 filing 144
- 2024-10-25 filing 144
- 2024-10-23 filing Quarterly report (10-Q)
- 2024-10-23 filing 8-K items 2.02,9.01
- 2024-09-20 filing 144
- 2024-09-20 filing 144
- 2024-08-21 filing 144
- 2024-08-21 filing 144
- 2024-08-19 filing 144
- 2024-08-19 filing 144
- 2024-08-14 filing 144
- 2024-07-30 filing 144
- 2024-07-30 filing 144
- 2024-07-30 filing 144
- 2024-07-24 filing Quarterly report (10-Q)
- 2024-07-24 filing 8-K items 2.02,9.01
- 2024-06-04 filing 8-K items 7.01,9.01
- 2024-05-23 officer change 8-K items 5.02,5.07,9.01
- 2024-05-23 filing S-8 POS
- 2024-05-23 filing S-8 POS
- 2024-05-23 filing S-8 POS
- 2024-05-23 filing S-8 POS
- 2024-05-23 filing S-8 POS
- 2024-05-23 filing S-8 POS
- 2024-05-23 filing S-8 POS
- 2024-05-23 filing S-8 POS
- 2024-05-23 filing S-8 POS
- 2024-05-23 filing S-8 POS
- 2024-05-22 filing S-8 POS
- 2024-05-22 filing S-8
- 2024-05-03 filing 144
- 2024-05-01 filing 144
- 2024-04-25 filing Quarterly report (10-Q)
- 2024-04-24 filing 8-K items 2.02,9.01
- 2024-04-05 filing ARS
- 2024-04-05 filing DEFA14A
- 2024-04-05 filing Proxy statement
- 2024-03-26 filing 8-K items 7.01,9.01
- 2024-03-04 filing 8-K items 8.01,9.01
- 2024-03-01 filing 424B5
- 2024-03-01 filing 8-K items 1.01,8.01,9.01
- 2024-02-27 filing 424B5
- 2024-02-27 filing 8-K items 7.01,9.01
- 2024-02-09 filing 144
- 2024-02-08 filing 144
- 2024-02-08 filing 144
- 2024-02-07 filing S-8
- 2024-02-07 filing Annual report (10-K)
- 2024-02-07 filing 8-K items 2.02,9.01
- 2024-01-31 filing 144
- 2024-01-30 filing 144
- 2024-01-19 filing 144
- 2024-01-04 filing 144
- 2023-10-25 filing Quarterly report (10-Q)
- 2023-10-25 filing 8-K items 2.02,9.01
- 2023-07-26 filing S-3ASR
- 2023-07-26 filing Quarterly report (10-Q)
- 2023-07-26 filing 8-K items 2.02,9.01
- 2023-06-14 filing 8-K items 5.07,9.01
- 2023-05-16 filing 144
- 2023-05-16 filing 144
- 2023-05-11 filing 8-K items 5.03,9.01
- 2023-05-01 filing ARS
- 2023-05-01 filing DEFA14A
- 2023-05-01 filing Proxy statement
- 2023-05-01 filing 144
- 2023-04-26 filing Quarterly report (10-Q)
- 2023-04-26 filing 8-K items 2.02,9.01
- 2023-04-24 filing 144
- 2023-04-19 filing 144
- 2023-04-17 filing 144
- 2023-04-17 filing 144
- 2023-04-17 filing 144
- 2023-04-17 filing 144
- 2023-04-17 filing 144
- 2023-04-17 filing PRE 14A
- 2023-04-03 filing 8-K items 8.01,9.01
- 2023-03-31 filing 8-K items 1.01,8.01,9.01
- 2023-03-31 filing 424B5
- 2023-03-30 filing SC 13D/A
- 2023-03-29 filing 424B5
- 2023-03-28 filing 8-K items 7.01,9.01
- 2023-03-28 filing 8-K items 7.01,9.01
- 2023-02-10 filing S-8
- 2023-02-10 filing Annual report (10-K)
- 2023-02-09 filing SC 13D/A
- 2023-02-08 filing 8-K items 2.02,9.01
- 2022-10-26 filing Quarterly report (10-Q)
- 2022-10-26 filing 8-K items 2.02,9.01
- 2022-07-27 filing Quarterly report (10-Q)
- 2022-07-27 filing 8-K items 2.02,9.01
- 2022-05-26 filing 8-K items 5.07
- 2022-04-27 filing Quarterly report (10-Q)
- 2022-04-27 filing 8-K items 2.02,9.01
- 2022-04-07 filing DEFA14A
- 2022-04-07 filing Proxy statement
- 2022-02-09 filing S-8
- 2022-02-09 filing Annual report (10-K)
- 2022-02-09 filing 8-K items 2.02,9.01
- 2021-11-03 filing Quarterly report (10-Q)
- 2021-11-03 filing 8-K items 2.02,9.01
- 2021-08-11 filing EFFECT
- 2021-08-11 filing 424B5
- 2021-08-05 filing CORRESP
- 2021-08-02 filing UPLOAD
- 2021-07-28 filing 8-K items 1.01,1.02,9.01
- 2021-07-28 filing S-3
- 2021-07-28 filing Quarterly report (10-Q)
- 2021-07-28 filing 8-K items 2.02,9.01
- 2021-05-21 filing 8-K items 5.07
- 2021-04-28 filing Quarterly report (10-Q)
- 2021-04-28 filing 8-K items 2.02,9.01
- 2021-04-08 filing DEFA14A
- 2021-04-08 filing Proxy statement
- 2021-04-08 filing 25-NSE
- 2021-02-17 filing S-8
- 2021-02-17 filing Annual report (10-K)
- 2021-02-17 filing 8-K items 2.02,9.01
- 2021-01-06 officer change 8-K items 5.02,9.01
- 2020-10-28 filing Quarterly report (10-Q)
- 2020-10-28 filing 8-K items 2.02,9.01
- 2020-08-28 filing SC 13D/A
- 2020-07-29 filing Quarterly report (10-Q)
- 2020-07-29 filing 8-K items 2.02,9.01
- 2020-05-21 filing 8-K items 5.07
- 2020-05-20 filing DEFA14A
- 2020-04-30 filing Quarterly report (10-Q)
- 2020-04-30 filing 8-K items 2.02,9.01
- 2020-04-06 filing DEFA14A
- 2020-04-06 filing Proxy statement
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-10-29 (within 30 days) 10-Q filed
- 2026-10-28 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-09-28 (older) 8-K filed: Item 1.01 material agreement; Item 2.03 new financial obligation; Item 9.01 exhibits
- 2026-09-25 (older) 424B5 filed
- 2026-09-25 (older) 424B5 filed
- 2026-09-24 (older) FWP filed (FREE WRITING PROSPECTUS)
- 2026-09-24 (older) 305B2 filed (APPLICATION FOR DESIGNATION OF A NEW TRUSTEE)
- 2026-09-23 (older) 424B5 filed
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-20; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:VKTX The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
2 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1607678 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | VKTX / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| LEI (root of the ownership tree) | 529900IVC72YPFA25M37 | id:lei-family: legal entity in this company's GLEIF ownership tree (LEI 529900IVC72YPFA25M37) | GLEIF |
| EIN | 461073877 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001607678 | SEC EDGAR / IRS |
| CUSIP | 92686J106 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001607678 | SEC EDGAR |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $0 | 2025-12-31 | 10-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax | as filed | 2026-11-20 08:08 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | -$359,639,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-20 08:08 UTC | Report an error |
| Total assets (at 2025-12-31) | $715,729,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-20 08:08 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $639,062,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-20 08:08 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $165,810,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-20 08:08 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-05 | SEC EDGAR company profile | as filed | 2026-11-20 08:08 UTC | Report an error |
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-05 | SEC EDGAR company profile | as filed | 2026-11-20 08:08 UTC | Report an error |
| State of incorporation | DE | 2026-11-05 | SEC EDGAR company profile | as filed | 2026-11-20 08:08 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-05 | SEC EDGAR company profile | as filed | 2026-11-20 08:08 UTC | Report an error |
| Business address | 9920 PACIFIC HEIGHTS BLVD, SUITE 500, SAN DIEGO, CA | 2026-11-05 | SEC EDGAR company profile | as filed | 2026-11-20 08:08 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-05 | SEC EDGAR company profile | as filed | 2026-11-20 08:08 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$278,685,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-20 08:08 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $137,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-20 08:08 UTC | Report an error |
| Form D total offering amount (D filed 2017-06-22) | $3,656,038 | 2017-06-22 | D | as filed | 2026-11-20 08:08 UTC | Report an error |
| Form D total amount sold (D filed 2017-06-22) | $0 | 2017-06-22 | D | as filed | 2026-11-20 08:08 UTC | Report an error |
| Form D industry group | Biotechnology | 2017-06-22 | D | as filed | 2026-11-20 08:08 UTC | Report an error |
| Form D revenue range | No Revenues | 2017-06-22 | D | as filed | 2026-11-20 08:08 UTC | Report an error |
| Form D date of first sale | 2017-06-19 | 2017-06-22 | D | as filed | 2026-11-20 08:08 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-10-29 · accession 0001193125-26-436432
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | 3 months ended 2026-09-30 | 10-Q | 2026-10-29 | 0001193125-26-436432 | 2026-11-20 08:08 UTC | Report an error |
| Net income (loss) | -$183,186,000 | 3 months ended 2026-09-30 | 10-Q | 2026-10-29 | 0001193125-26-436432 | 2026-11-20 08:08 UTC | Report an error |
| Interest expense | $88,000 | 3 months ended 2026-09-30 | 10-Q | 2026-10-29 | 0001193125-26-436432 | 2026-11-20 08:08 UTC | Report an error |
| Cash and cash equivalents | $677,609,000 | at 2026-09-30 | 10-Q | 2026-10-29 | 0001193125-26-436432 | 2026-11-20 08:08 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-10-29 Filing 10-Q filed
- 2026-10-28 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-09-28 Filing 8-K filed: Item 1.01 material agreement; Item 2.03 new financial obligation; Item 9.01 exhibits
- 2026-09-25 Filing 424B5 filed
- 2026-09-25 Filing 424B5 filed
- 2026-09-24 Filing FWP filed (FREE WRITING PROSPECTUS)
- 2026-09-24 Filing 305B2 filed (APPLICATION FOR DESIGNATION OF A NEW TRUSTEE)
- 2026-09-23 Filing 424B5 filed
- 2026-09-23 Filing 424B5 filed
- 2026-09-22 Filing 8-K filed: Item 8.01 other event; Item 9.01 exhibits
- 2026-07-30 Filing S-3ASR filed
- 2026-07-29 Filing 10-Q filed
- 2026-07-29 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-05-26 Filing 8-K filed: Item 5.07 shareholder vote; Item 9.01 exhibits
- 2026-04-30 Filing 10-Q filed
- 2026-04-29 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-04-01 Filing ARS filed
- 2026-04-01 Filing DEFA14A filed
- 2026-04-01 Filing DEF 14A filed
- 2026-02-11 Filing 10-K filed
- 2026-02-11 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-10-23 Filing 10-Q filed
- 2025-10-22 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-08-19 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 9.01 exhibits
- 2025-07-23 Filing 10-Q filed
8-K item text, as filed (excerpts)
- 2026-10-28 8-K Item 2.02, Results of Operations and Financial Condition
On October 28, 2026, we issued a press release reporting our financial results for the third quarter ended September 30, 2026 and providing a corporate update. The full text of the press release is furnished as exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. In accordance with General Instructions B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed… the 8-K · retrieved 2026-11-20 08:08 UTC - 2026-09-28 8-K Item 1.01, Entry into a Material Definitive Agreement
Equity Offering On September 23, 2026, Viking Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Equity Underwriting Agreement”) with Morgan Stanley & Co. LLC and J.P. Morgan Securities LLC (the “Equity Representatives”), as representatives of the several underwriters named therein (the “Equity Underwriters”), to issue and sell (the “Equity Offering”) 7,857,143 shares of the Company’s common stock, par value $0.00001 per share (“Common Stock”), at a public offering price of $35.00 per share. Under the terms of the Equity Underwriting Agreement, the Company also granted the Equity Underwriters a 30-day option to purchase up to an additional 1,178,571 shares of… the 8-K · retrieved 2026-11-20 08:08 UTC - 2026-09-28 8-K Item 2.03, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
The information set forth under the heading “Debt Offering” in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements that involve risks and uncertainties, such as statements related to the estimated offering expenses of, and anticipated use of proceeds from, the Equity Offering and Debt Offering. The risks and uncertainties involved include those detailed in the final prospectus supplements for the offerings and from time to time in the Company’s periodic reports and other filings with the SEC. You are cautioned not to place undue reliance on forward-looking statements… the 8-K · retrieved 2026-11-20 08:08 UTC - 2026-09-22 8-K Item 8.01, Other Events
On September 22, 2026, Viking Therapeutics, Inc. issued a press release announcing top-line results from its maintenance study of GLP-1/GIP agonist VK2735. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. the 8-K · retrieved 2026-11-20 08:08 UTC - 2026-07-29 8-K Item 2.02, Results of Operations and Financial Condition
On July 29, 2026, we issued a press release reporting our financial results for the second quarter ended June 30, 2026 and providing a corporate update. The full text of the press release is furnished as exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. In accordance with General Instructions B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under… the 8-K · retrieved 2026-11-20 08:08 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | $247,157,830 | 2026-06-30 | SEC 13F filing | 2026-11-20 08:08 UTC | Report an error |
| 2 | BlackRock, Inc. | $241,458,213 | 2026-06-30 | SEC 13F filing | 2026-11-20 08:08 UTC | Report an error |
| 3 | STATE STREET CORP | $218,705,430 | 2026-06-30 | SEC 13F filing | 2026-11-20 08:08 UTC | Report an error |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | $197,143,394 | 2026-06-30 | SEC 13F filing | 2026-11-20 08:08 UTC | Report an error |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | $174,931,100 | 2026-06-30 | SEC 13F filing | 2026-11-20 08:08 UTC | Report an error |
| 6 | TWO SIGMA INVESTMENTS, LP | $153,598,520 | 2026-06-30 | SEC 13F filing | 2026-11-20 08:08 UTC | Report an error |
| 7 | AMERIPRISE FINANCIAL INC | $84,108,797 | 2026-06-30 | SEC 13F filing | 2026-11-20 08:08 UTC | Report an error |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | $81,865,360 | 2026-06-30 | SEC 13F filing | 2026-11-20 08:08 UTC | Report an error |
| 9 | AMERICAN CENTURY COMPANIES INC | $70,844,186 | 2026-06-30 | SEC 13F filing | 2026-11-20 08:08 UTC | Report an error |
| 10 | D. E. Shaw & Co., Inc. | $62,649,826 | 2026-06-30 | SEC 13F filing | 2026-11-20 08:08 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
GLEIF OWNERSHIP TREE · ID TIER11. Subsidiaries
1 legal entity in the company's GLEIF ownership tree, joined by LEI (an official identifier).
- VIKING THERAPEUTICS, INC. · LEI 529900IVC72YPFA25M37 · root
Exhibit 21 subsidiaries: not held yet.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
2 state and city records carry this company's exact name, from 2 sources. Possible matches only.
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchViking Therapeutics, Inc. · exact legal name · sx:ctgov:h5fb40dbca00d1aa0 Compare
New York corporations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchVIKING THERAPEUTICS, INC. · exact legal name · sx:nydos:4302196 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1607678.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001607678. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.